Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

Key Takeaway: SI-BONE, Inc. has announced it will report its financial results for the first quarter of 2025 on May 5, 2025, following market close. The company is recognized as a leader in developing surgical technologies for sacropelvic disorders and has a significant history of supporting medical professionals in this field. A conference call will be held at 1:30 p.m. PT on the same day for investors to discuss the results. Live audio of the call will be accessible via the company's website.
Price reaction · baseline $13.37 (2025-04-11 close) · clean, no other SIBN news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE continues to lead in minimally invasive SI joint surgery.
  • Over 4,300 physicians trained and 115,000 procedures performed.
  • Strong clinical evidence with randomized controlled trials supporting their technologies.

Full Press Release Details

SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/ueassh6s. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE report its Q1 2025 financial results?

SI-BONE will report its Q1 2025 financial results on May 5, 2025.

How can investors listen to the SI-BONE conference call?

Investors can register for the call at https://edge.media-server.com/mmc/p/ueassh6s.

What is SI-BONE's expertise in medical technology?

SI-BONE specializes in surgical treatments for sacropelvic disorders.

How many procedures has SI-BONE supported since 2009?

SI-BONE has supported over 115,000 procedures since 2009.

Where can I find more information about SI-BONE?

More information can be found at www.si-bone.com.

Last updated: Apr 14, 2025